These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2552911)

  • 1. In vitro studies of Chlamydia trachomatis susceptibility and resistance to rifampin and rifabutin.
    Treharne JD; Yearsley PJ; Ballard RC
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1393-4. PubMed ID: 2552911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis.
    Jones RB; Ridgway GL; Boulding S; Hunley KL
    Rev Infect Dis; 1983; 5 Suppl 3():S556-61. PubMed ID: 6635445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.
    Kutlin A; Kohlhoff S; Roblin P; Hammerschlag MR; Riska P
    Antimicrob Agents Chemother; 2005 Mar; 49(3):903-7. PubMed ID: 15728882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.
    Suchland RJ; Bourillon A; Denamur E; Stamm WE; Rothstein DM
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1120-6. PubMed ID: 15728912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
    Dickinson JM; Mitchison DA
    Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro susceptibility studies of FCE 22250 and rifampicin on Legionella and Chlamydia trachomatis strains.
    Zanetti S; Ungheri D; Castellani Pastoris M; Fadda G
    Drugs Exp Clin Res; 1987; 13(10):631-4. PubMed ID: 3428127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative in vitro activities of rifabutin and rifampicin against various mycobacteria using 7H10 agar and 1% Ogawa egg media].
    Sato K; Saito H; Tomioka H
    Kekkaku; 1988 Sep; 63(9):601-4. PubMed ID: 2854588
    [No Abstract]   [Full Text] [Related]  

  • 8. [In vitro activities of rifabutine and rifampicin against various mycobacteria, especially Mycobacterium tuberculosis and Mycobacterium avium complex].
    Saito H; Sato K; Tomioka H
    Kekkaku; 1988 Mar; 63(3):167-72. PubMed ID: 2836649
    [No Abstract]   [Full Text] [Related]  

  • 9. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
    Dhillon J; Mitchison DA
    Am Rev Respir Dis; 1992 Jan; 145(1):212-4. PubMed ID: 1309967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis.
    Zanetti S; Usai D; Nonis A; Fadda G
    J Antimicrob Chemother; 1996 Feb; 37(2):357-9. PubMed ID: 8707747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis.
    Heifets LB; Lindholm-Levy PJ; Iseman MD
    Am Rev Respir Dis; 1988 Mar; 137(3):719-21. PubMed ID: 2830815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis.
    Bodmer T; Zürcher G; Imboden P; Telenti A
    J Antimicrob Chemother; 1995 Feb; 35(2):345-8. PubMed ID: 7759399
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.
    Dreses-Werringloer U; Padubrin I; Zeidler H; Köhler L
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3001-8. PubMed ID: 11600348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.
    Woodley CL; Kilburn JO
    Am Rev Respir Dis; 1982 Sep; 126(3):586-7. PubMed ID: 6289711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of rifamycins in HIV-infected patients.
    Preboth M
    Am Fam Physician; 2000 Sep; 62(5):1189-90. PubMed ID: 10997538
    [No Abstract]   [Full Text] [Related]  

  • 16. Rapid detection of rifampin resistance in Mycobacterium tuberculosis isolates by heteroduplex analysis and determination of rifamycin cross-resistance in rifampin-resistant isolates.
    Saribaş Z; Kocagöz T; Alp A; Günalp A
    J Clin Microbiol; 2003 Feb; 41(2):816-8. PubMed ID: 12574290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.
    Murphy CK; Mullin S; Osburne MS; van Duzer J; Siedlecki J; Yu X; Kerstein K; Cynamon M; Rothstein DM
    Antimicrob Agents Chemother; 2006 Mar; 50(3):827-34. PubMed ID: 16495239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan.
    Chien HP; Yu MC; Ong TF; Lin TP; Luh KT
    J Formos Med Assoc; 2000 May; 99(5):408-11. PubMed ID: 10870331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis.
    Chan SL; Yew WW; Ma WK; Girling DJ; Aber VR; Felmingham D; Allen BW; Mitchison DA
    Tuber Lung Dis; 1992 Feb; 73(1):33-8. PubMed ID: 1326348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis.
    Xia M; Suchland RJ; Carswell JA; Van Duzer J; Buxton DK; Brown K; Rothstein DM; Stamm WE
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3974-6. PubMed ID: 16127086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.